Keppra is a trade name for levetiracetam, an anti-seizure medicine used to treat epilepsy, including partial-onset, myoclonic, and tonic-clonic seizures. It acts as an SV2A ligand and is available in oral and intravenous forms. Levetiracetam was approved for medical use in the United States in 1999.
Northwestern University researchers found that levetiracetam, an FDA-approved anti-seizure medication, prevents formation of toxic amyloid-beta 42 peptides in the brain, offering a potential strategy for early Alzheimer's prevention.
The FDA has authorized the first human trial of an allogeneic stem cell therapy for epilepsy, developed by Shanghai-based Unixell Biotechnology. The therapy uses donor-derived stem cells to produce GABA and suppress seizures in drug-resistant patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07490769 |
Levetiracetam Three Times Daily in Epilepsy |
RECRUITING | PHASE3 |
| NCT07401433 |
Levetiracetam Versus Phenobarbitone for the Treatment of Neonatal Seizures in a Tertiary Care Hospital. |
COMPLETED | NA |
| NCT07284498 |
Treatment of Seizures in Neonate With HIE |
NOT_YET_RECRUITING | PHASE4 |
| NCT07239115 |
Levetiracetam for Seizure Prevention After Brain Tumor Surgery |
NOT_YET_RECRUITING | PHASE3 |
| NCT07220902 |
Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure |
NOT_YET_RECRUITING | PHASE3 |
| NCT07163585 |
Comparison of Oral Brivaracetam Versus Levetiracetam as Monotherapy in Epilepsy |
COMPLETED | NA |
| NCT07072624 |
Early Post-Traumatic Seizures Prevention Trial (E-PTS Trial) |
RECRUITING | PHASE4 |
| NCT07052136 |
Efficacy Comparison Between Levetiracetam and Valproic Acid in Pediatric Patients With Status Epilepticus |
COMPLETED | NA |
| NCT07046611 |
Ketamine and Levetiracetam as Second-line Antiseizure Medication for Status Epilepticus in Children |
RECRUITING | PHASE2/PHASE3 |
| NCT06866691 |
Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide |
RECRUITING | PHASE4 |
